BioSpace News Archive

Genetown

Flex Pharma Reports Third Quarter 2017 Financial Results

Flex reported financial results for the quarter ended September 30, 2017 and provided an update on its clinical development and corporate activities.

November 6, 2017
·
11 min read
Biotech Bay

Guardant Health Database Reveals Potential of Targeted Therapy Combinations to Treat Advanced Lung Cancer

The findings, published in Nature Genetics, suggest that physicians may need to reevaluate the current practice of selecting treatment based on the detection of single genomic biomarkers.

November 6, 2017
·
2 min read
BioMidwest

Northwestern Medicine’s Clinical Trial Targets Devastating Heart Failure Diagnosis

Lynne Austin found she was increasingly out of breath doing even the simplest of tasks as 2015 came to a close.

November 6, 2017
·
4 min read
FDA

Abbott’s MitraClip Approved as First Transcatheter Mitral Valve Repair Device in Japan

The MitraClip system is a catheter-based, minimally-invasive therapy that is delivered to the heart through a blood vessel in the leg.

November 6, 2017
·
4 min read
Drug Development

Themis to Present Phase II Interim Results for Chikungunya Vaccine Candidate at ASTMH 2017 Annual Meeting

The data will be presented today for the first time at the Annual Meeting of the ASTMH in Baltimore, MA, USA.

November 6, 2017
·
2 min read
Business

Strongbridge Biopharma plc to Host Third Quarter 2017 Financial Results Conference Call on November 14, 2017

The conference call will follow the anticipated release of the Company’s financial results earlier that day.

November 6, 2017
·
2 min read
Policy

KemPharm Receives USAN Approval for “Asalhydromorphone” as Nonproprietary Name for Novel Prodrug Candidate, KP511

Asal-HM is a prodrug of hydromorphone being developed as a potentially less abusable hydromorphone product for the treatment of pain severe enough to require daily, long-term opioid treatment.

November 6, 2017
·
5 min read
Pharm Country

QuintilesIMS is now IQVIA

Beginning on November 15, 2017, equity shares of the company will trade on the NYSE under the new name and new ticker symbol “IQV.”

November 6, 2017
·
3 min read
Business

Minerva Neurosciences Reports Third Quarter 2017 Financial Results and Business Updates

Cash, cash equivalents and marketable securities as of September 30, 2017 were approximately $143.3 million, compared to $83.0 million as of December 31, 2016.

November 6, 2017
·
9 min read
Business

Avinger Enters Into Common Stock Purchase Agreement for up to $15M With Lincoln Park Capital

The Company is filing a registration statement with the SEC relating to the transaction.

November 6, 2017
·
4 min read